Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
Basal cell carcinoma (BCC) is the most common form of skin cancer and occurs predominantly as two forms, nodular or superficial. We report cases of two females who presented with facial BCCs, one with a 2-month history of superficial BCC with a dual growth pattern (superficial BCC overlying a deep micronodular pattern BCC), and the other with a 4-year history of superficial BCC. Both patients had undergone previous unsuccessful treatments. Differing responses of facial superficial BCCs were observed following daily treatment with imiquimod 5% cream over 6 weeks. This included a treatment failure in the BCC with a dual growth pattern and complete clearance of the other superficial BCC.
Mirza
B
B
South East Dermatology, Brisbane, Queensland, Australia. basitmirza@hotmail.com
De'Ambrosis
B
B
D000287:Administration, Topical; D000328:Adult; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D005153:Facial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008875:Middle Aged; D009824:Ointments; D013472:Sunlight / Q000009:adverse effects; D016896:Treatment Outcome
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D009824:Ointments; D000077271:Imiquimod